



Celldex Therapeutics, Inc.
Investor Relations Department
119 Fourth Avenue
Needham, MA 02494-2725
United States

[Visit IR website](#)
[Sign-up for email alerts](#)

NASDAQ: CLDX ¹	
Last Trade:	2.79
Trade Time:	4:00 PM ET Oct 23, 2017
Change:	-0.13 (4.452%)
Day Range	2.68 - 2.94
52-Week Range	2.20 - 5.02
Volume	1,920,982
Market Cap. (\$M)	358.069
Shares Out (M)	128.340

¹ The stock information is provided by eSignal, stock charts are provided by EDGAR Online. Stock information is delayed approximately 20 minutes.

Company Profile

Celldex Therapeutics, Inc. is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. Our pipeline is built from a proprietary portfolio of antibodies and immunomodulators used alone and in strategic combinations to create novel, disease-specific therapies that induce, enhance or suppress the body's immune response.

... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

- Oct 3, 2017*
[Celldex Therapeutics Appoints Margo Heath-Chiozzi, M.D., as Senior Vice President, Regulatory Affairs](#)
- Sep 22, 2017*
[Celldex Therapeutics to Present at the Cantor Fitzgerald Global Healthcare Conference](#)
- Sep 12, 2017*
[Celldex Announces Departure of Chief Medical Officer](#)
- Aug 23, 2017*
[Celldex Announces Completion of Enrollment in Phase 2b Study of Glembatumumab Vedotin in Triple Negative Breast Cancer](#)
- Aug 8, 2017*
[Celldex Reports Second Quarter 2017 Results](#)

Events [\[View all \]](#)

There are no events to display at this time. Please check back later.

Financials [\[View all \]](#)

[Second Quarter Financial Results](#)

- Mar 14, 2017*
[Annual Report \(10-K\)](#)
- Apr 28, 2017*
[Definitive Proxy Statement](#)
- Aug 8, 2017*
[Quarterly Report \(10-Q\)](#)
- May 9, 2017*
[Quarterly Report \(10-Q\)](#)
- Nov 7, 2016*
[Quarterly Report \(10-Q\)](#)